AOD-9604 and the hGH 176-191 Fragment: What a Fragment Keeps

AOD-9604 is a useful illustration of a general principle in peptide research: a fragment of a protein is a different molecule from the protein, with its own pharmacology that has to be established rather than inherited.

Derivation

Human growth hormone is a 191-residue protein. AOD-9604 corresponds to the C-terminal region — residues 176 to 191 — with a tyrosine added at the N-terminus. That single addition is a deliberate stabilisation, not an accident of synthesis.

What the fragment does not carry

The growth hormone receptor binding surface is distributed across the folded protein, not contained in the C-terminal sixteen residues. A short linear fragment cannot reconstruct that surface, so AOD-9604 is not expected to act as a growth hormone receptor agonist, and the literature treats it as mechanistically separate from hGH rather than as a smaller version of it.

This is worth stating plainly because catalogue copy across the industry often implies otherwise. The indexed literature is at PubMed.

Reading the literature

The published work is limited in volume and largely preclinical. As with other compounds in this position, findings reported in one model system and one laboratory should be treated as provisional until independently reproduced. Where a review cites a striking result, it is worth tracing back to the primary paper and checking the model, the concentration and the controls.

Handling

AOD-9604 contains a disulfide bridge derived from the parent sequence, which introduces a consideration most short linear peptides do not have: reducing agents in a buffer will open the bridge and change the molecule. Dithiothreitol and β-mercaptoethanol are not neutral additives here.

Identity confirmation by mass distinguishes the reduced and oxidised forms, since they differ by two mass units — worth checking on a certificate for any disulfide-containing peptide. See HPLC and mass spectrometry verification.

Sequence, and what a mass check is actually testing

The fragment is commonly reported with the sequence YLRIVQCRSVEGSCGF: sixteen residues, the N-terminal tyrosine described above followed by the hGH 177 to 191 stretch. The two cysteines sit at positions seven and fourteen within that numbering, and they are the pair that forms the bridge.

That sequence is what a mass spectrum is being compared against. A certificate should carry both a calculated mass for the intended sequence and an observed mass from the instrument, and the useful question is not whether an observed figure looks plausible but whether the two agree within the tolerance the method claims. A certificate that reports only one of the two numbers is not telling you anything you can check.

One consequence of the N-terminal tyrosine is analytically convenient regardless of why it was originally added: tyrosine absorbs at 280 nm, so the concentration of a reconstituted solution can be estimated by absorbance rather than inferred from the label. For a peptide with no tryptophan and a single tyrosine that measurement is coarse, but it is an independent check on a figure that otherwise rests entirely on the vial’s stated mass.

The disulfide is a storage question, not only a buffer question

The point above about dithiothreitol and beta-mercaptoethanol extends further than the reducing agent bottle.

Thiol-disulfide exchange is a chemistry that runs whenever a free thiol is present, and it accelerates markedly as pH rises above neutrality. A reducing agent left over in glassware, a buffer made up with a thiol-containing component, or a solution held at pH 8 for convenience will all move the equilibrium. In a peptide with a single bridge the visible result is a mixture of the intended cyclic form and a reduced open-chain form, and in mixtures containing more than one disulfide-bearing species the result can include scrambled products that are the same mass as the starting material.

The practical measures are the ordinary ones and they work: keep the material dry and sealed until use, reconstitute into a buffer at or slightly below neutral pH, avoid thiol-containing additives unless the experiment requires them, and aliquot so that a single stock is not opened repeatedly. Our notes on storage and stability and on where peptide impurities come from cover the general case.

What to look for on the certificate

Three things, in this order.

Identity by mass comes first, for the reason set out above: the reduced and oxidised forms differ by two mass units, which is a small enough difference that it has to be looked for deliberately rather than noticed in passing.

Purity by HPLC comes second, with the chromatogram rather than the headline percentage. A single sharp peak at 98% and a peak with a pronounced shoulder at 98% are different materials, and only one of those two facts appears in the number.

Net peptide content comes third and is the one most often overlooked. Synthetic peptides are typically supplied as trifluoroacetate salts, and the counter-ion plus residual water can account for a meaningful fraction of the vial’s mass. A vial labelled 5 mg contains 5 mg of powder, not necessarily 5 mg of peptide, and for any work where the concentration matters that distinction has to be resolved from the certificate rather than assumed. Our notes on net peptide content and counter-ions and salt form explain how the figures relate.

Product: AOD-9604 5mg, listed with other growth hormone pathway peptides.

ExoLabz supplies compounds for laboratory research use only. Nothing on this page is medical advice or a suggestion of human or veterinary use. Certificates of analysis are published on this site.